PROCEPT BioRobotics Corporation
$21.65-1.4%YTD-42.3%1Y-46.0%
Mentions · last 7 days
66
Price updated 3d ago·X counts updated 4d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $PRCT, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Devices sits in its cycle right now — and what that implies for $PRCT.
Medical - Devices
No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.
What this means for $PRCT
Partial — Makes the AquaBeam Robotic System for Aquablation therapy — a water-jet surgical robot for minimally invasive treatment of benign prostatic hyperplasia; partial earnings exposure to medical - devices demand dynamics through its product portfolio.
Industry benchmark
25-name peer basket
+9.7%YTD
+31.2%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-11.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-25.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-33.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-6.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
3.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-27.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
63.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.47$-0.46-1.8%
Q1 2026Apr 29, 2026$-0.56$-0.55-1.8%
Q4 2025Feb 25, 2026$-0.53$-0.32-65.6%
Q3 2025Nov 4, 2025$-0.38$-0.41+7.3%
Next earningsTue, Nov 3·consensus EPS $-0.39
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$83.1M+20.2%64.9%-39.2%$-0.56$-41.0M
Q4 FY25$76.4M+11.9%60.6%-40.6%$-0.53$-12.2M
Q3 FY25$83.3M+42.8%62.9%-27.8%$-0.38$-9.5M
Q2 FY25$79.2M+48.4%63.3%-28.0%$-0.35$-17.8M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$397.4M$392.6M – $403.4M-$1.54-$1.66 – -$1.4410
FY27$490.1M$485.2M – $495.0M-$0.90-$1.38 – -$0.6010
FY28$585.5M$569.7M – $612.3M-$0.62-$1.10 – -$0.328
FY29$681.6M$667.5M – $696.2M-$0.18-$0.18 – -$0.187
FY30$794.9M$778.5M – $811.9M$0.64$0.62 – $0.667
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.19%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+1.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-19.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 54.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.895-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary
8-KOfficer or director changeMar 68-K — Item 5.02: Officer or director change
8-KPress release / Reg FDFeb 268-K — Item 7.01: Press release / Reg FD
+ 15 other (5 13Gs · 3 earnings 8-Ks · 2 10-Qs · 2 proxys) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
PRCT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCTPRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud LawsuitPRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud LawsuitPRCT DEADLINE NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCTINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT
More in Medical - Devices
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 2 · last 7 days